diphenhydramine HCl

DRUG3 trials

Sponsors

Johnson & Johnson Consumer and Personal Products Worldwide, Bayer, National Cancer Institute (NCI)

Conditions

Allergic RhinitisCarcinoma In SituCervical Intraepithelial NeoplasiaPapillomavirus InfectionsTherapeutic EquivalenceVulvar DiseasesVulvar Neoplasms

Phase 1

Study to Evaluate Diphenhydramine in Children and Adolescents

CompletedNCT00762749

Johnson & Johnson Consumer and Personal Products WorldwideAllergic Rhinitis

Start: 2008-09-30End: 2008-11-30Updated: 2011-10-06

Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination

CompletedNCT01666678

BayerTherapeutic Equivalence

Start: 2012-01-31End: 2012-03-31Updated: 2014-08-21

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

CompletedNCT02858310

National Cancer Institute (NCI)Carcinoma In Situ, Cervical Intraepithelial Neoplasia, Papillomavirus Infections +2

Start: 2017-01-27End: 2025-07-02Updated: 2026-03-09

Related Papers

TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.

2021-02-08258 citations

Safety and clinical activity of gene-engineered T-cell therapy targeting HPV-16 E7 for epithelial cancers.

Journal of Clinical Oncology2020-05-2020 citations

Engineered t cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.

Journal of Clinical Oncology2018-05-205 citations

Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model

JCI Insight2018-04-18159 citations